PharmaMar (MSE:PHM) has announced today that the World Health Organization (WHO) has confirmed the International Nonproprietary Name (INN) of its investigational anti-tumor compound PM14 as ecubectedin.
The WHO has published a list of recommended INNs on its website, including this new name for PharmaMar's active ingredient, which means that it can now be used officially.
Ectubectedin is currently in Phase I-II clinical development, both as a single agent and in combination with other drugs for the treatment of solid tumors. The four ongoing clinical trials with this compound are being conducted in 12 hospitals in Spain, France, the United Kingdom and the United States.
Ecubectedin is a compound that acts by specifically inhibiting RNA synthesis and active transcription of protein-coding genes.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.